At the news
? BULLISHIMPACT 7/10 8-K filed Jul 16, 2026 at 08:35 ET
Harmony Biosciences pre-announced record Q2 2026 WAKIX net product revenue of ~$261M (+30% YoY), reaffirmed full-year guidance of $1.0B-$1.04B, and disclosed the immediate departure of CFO Glenn Reicin (hired only ~3 months ago) with the controller appointed as interim CFO. The revenue beat is strongly positive, but the abrupt CFO departure introduces governance uncertainty that partially offsets the bullish signal.
- Q2 2026 preliminary WAKIX net product revenue of ~$261M, a record quarter, representing 30% YoY growth and 21% sequential growth over Q1 2026
- Reaffirmed full-year 2026 net product revenue guidance of $1.0B to $1.04B
- CFO Glenn Reicin stepped down effective July 16, 2026 to pursue other opportunities; employed only since April 14, 2026 (~3 months)
- Stephen Mollichella, SVP & Controller, appointed Interim Principal Financial Officer
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access